Non-HDL cholesterol, ApoB and LDL particle concentration in coronary heart disease risk prediction and treatment

Abstract

LDL cholesterol has been identified as the primary therapeutic target for lipid management to reduce the future risk of coronary events. Despite the use of LDL cholesterol-targeted therapy with statins and other lipid-altering agents, many patients still suffer coronary events. Residual risk for such events has been attributed, at least in part, to persistently elevated atherogenic particle concentration. When patients are found to have elevated non-HDL cholesterol, ApoB-100 or LDL particle concentrations, they are presumed to be at increased risk and are often prescribed more aggressive lipid-altering therapy. This review examines the evidence that these biomarkers provide additional clinically useful information both in coronary risk prediction and in lipid management decision-making.

Keywords:

• ApoB
• biomarkers for coronary heart disease
• coronary heart disease risk prediction
• LDL particle concentration
• LDL particle number
• non-HDL cholesterol